Press Releases

SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on
May 12, 2022
SUNNYVALE, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Cowen
February 25, 2022
SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Citi
February 17, 2022
Third quarter revenue of $57 million  Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials  Vision of genetics-based primary care offers potential for millions of people to live healthier lives SUNNYVALE, Calif., Feb.
February 10, 2022
SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market closes on Thursday, February
January 27, 2022
Displaying 11 - 19 of 19
Print Page
RSS Feeds
Email Alerts
Contact IR